Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
This article was originally published in The Pink Sheet Daily
Executive Summary
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.